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carnosine is a dipeptide abundantly found in human skeletal muscle, cardiac muscle and neuronal cells 
having numerous properties that confers performance enhancing effects, as well as a wide-range of 
potential therapeutic applications. A reliable and valid method for tissue carnosine quantification is 
crucial for advancing the knowledge on biological processes involved with carnosine metabolism. In this 
regard, proton magnetic resonance spectroscopy (1H-MRS) has been used as a non-invasive alternative 
to quantify carnosine in human skeletal muscle. However, carnosine quantification by 1H-MRS has 
some potential limitations that warrant a thorough experimental examination of its validity. The 
present investigation examined the reliability, accuracy and sensitivity for the determination of muscle 
carnosine in humans using in vitro and in vivo experiments and comparing it to reference method for 
carnosine quantification (high-performance liquid chromatography – HPLC). We used in vitro 1H-MRS 
to verify signal linearity and possible noise sources. Carnosine was determined in the m. gastrocnemius 
by 1H-MRS and HPLC to compare signal quality and convergent validity. 1H-MRS showed adequate 
discriminant validity, but limited reliability and poor agreement with a reference method. Low signal 
amplitude, low signal-to-noise ratio, and voxel repositioning are major sources of error.
Carnosine is a multifunctional dipeptide abundantly found in human skeletal muscle, cardiac muscle, and in 
some neuronal cells1. Carnosine has numerous properties that confers performance enhancing effects2, as well 
as a wide-range of potential therapeutic applications3,4. Such properties include hydrogen cation (H+) buffering5, 
scavenging of reactive species6, and protection against glycation end products7. Several studies have demonstrated 
the beneficial effects of increased muscle carnosine content (for a comprehensive review, see 1), which can be 
easily achieved via dietary supplementation of β-alanine, the rate-limiting precursor of carnosine synthesis8.
A reliable and valid method for tissue carnosine quantification is crucial for advancing the knowledge on 
biological processes involved with carnosine metabolism, including whether its properties translate into relevant 
roles for normal physiological function and disease prevention. In human skeletal muscle, carnosine has been 
quantified in biopsy samples followed by chromatography8,9 or mass-spectrometry6. Even though obtaining mus-
cle biopsies is a relatively simple and safe procedure10, the invasive nature of the muscle biopsy technique limits its 
application, which warrants the development of valid and reliable non-invasive alternatives.
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In this regard, proton magnetic resonance spectroscopy (1H-MRS) has been used as a non-invasive alternative 
to quantify carnosine in human skeletal muscle11–13. In 1H-MRS, carnosine is quantified from two detectable sig-
nals emitted by the carbon four (C4-H) and the carbon two (C2-H) of the imidazole ring, which resonate at seven 
and eight ppm of the magnetic resonance spectrum14. Although 1H-MRS has been used to quantify carnosine 
in numerous investigations, there has not been any comprehensive investigation of the validity of 1H-MRS for 
muscle carnosine assessment against a reference method, such as the chromatographic determination in muscle 
biopsy samples.
Carnosine quantification by 1H-MRS has some potential limitations that warrant a thorough experimen-
tal examination. Firstly, in vivo carnosine signals are broad, of small amplitude, often close to the noise level, 
and tend to suffer dipolar coupling, in particular the signal emitted by C4-H14. This makes C4-H quantification 
unfeasible in most cases14. Secondly, the in vivo spectrum is crowded with metabolite peaks, thereby making car-
nosine identification particularly challenging, even when prior knowledge-based approaches are used15,16. Thus, 
carnosine quantification appears to be more difficult than other abundant muscle metabolites, such as creatine, 
taurine and lactate17. Thirdly, the signals emitted by the imidazole ring could, in theory, also be detected in other 
imidazole-containing molecules, such as free imidazole, free histidine, carnosine analogues and histidine residues 
in proteins. In fact, previous investigations have reported problems in differentiating signals from carnosine and 
its analogue homocarnosine in human brain18. This could represent a confounding factor for carnosine quanti-
fication by 1H-MRS. Fourthly, carnosine concentrations are not homogenous in muscle tissue, since fibre type 
distribution may affect local carnosine concentrations9,19. Also, fat tissue surrounding the measurement area can 
suppress the 1H-MRS signal, adding another source of variation to the carnosine signal14–16. Lastly, other vari-
ables, such as the signal-to-noise ratio, different angle and/or site of quantification, different machine operators 
and different data treatment can have major influences on metabolite quantification14–16,20,21.
To address the potential limitations of 1H-MRS to quantify carnosine in human skeletal muscle, the present 
investigation examined the reliability, accuracy and sensitivity of 1H-MRS for the determination of muscle car-
nosine in humans using in vitro and in vivo experiments. Carnosine determination by high-performance liquid 
chromatography (HPLC) in extracts from human muscle biopsy samples was used as the reference method.
Results
1H-MRS loses signal quality when measuring muscle carnosine in-vivo. To examine whether sig-
nal quality is affected when carnosine is measured in vivo (i.e., matrix effect), the signal obtained from a pure 
carnosine solution (12.5 mmol·L−1 carnosine phantom solidified in 2% agarose) was compared with the signal 
obtained in vivo from human calf muscle displaying similar carnosine concentration (10.4 mmol·L−1). Pure car-
nosine phantom showed excellent signal quality, with sharp peaks and high signal-to-noise ratio (Fig. 1, upper 
panel), whereas the signal obtained in vivo showed broadened peaks of lower intensity and lower signal-to-noise 
ratio (Fig. 1, lower panel).
1H-MRS detects signal emitted by small, but not large, imidazole-containing molecules. To 
examine the potential interference of other sources of imidazole ring to the carnosine signal obtained in vivo, we 
performed a series of in vitro 1H-MRS acquisitions in phantoms containing pure imidazole (12.5 mmol·L−1), pure 
histidine (equivalent to imidazole 12.5 mmol·L−1), pure carnosine (equivalent to imidazole 12.5 mmol·L−1) and 
pure protein (bovine serum albumin, BSA, equivalent to imidazole 12.5 mmol·L−1).
Signals were quantifiable in the phantoms containing imidazole, histidine and carnosine, but not in the phan-
tom containing protein (Fig. 2), indicating that small molecules containing imidazole are potential interferences 
in carnosine quantification, whereas histidine residues in large proteins are not. The carnosine signal was sharp 
and of low noise, whilst imidazole and histidine signals were less sharp and had larger noise in relation to their 
amplitude.
1H-MRS displays excellent signal linearity within the physiological concentration range. To 
assess signal linearity of small imidazole-containing molecules, a series of acquisitions were performed in phan-
toms containing different concentrations of pure imidazole (12.5, 25.0 and 50.0 mmol·L−1), pure carnosine 
(equivalent to 3.0, 4.5, 6.0, 12.5, 25.0 and 50.0 mmol·L−1 of imidazole) and pure histidine (equivalent to 12.5, 25.0 
and 50.0 mmol·L−1 of imidazole). Excellent signal linearity was shown for all substances within the concentration 
range assayed (Fig. 3).
HPLC as a reference method. In order to confirm that HPLC could be used as a reference method, and 
to account for all major sources of error associated with this method, we determined intra-assay reliability (i.e., 
same extract, from the same muscle sample, analysed on two separated runs; n = 15 m. vastus lateralis samples), 
inter-extract reliability (i.e., two different extracts, from the same muscle sample, analysed on two separated runs; 
n = 11 m. vastus lateralis samples) and inter-biopsy reliability (two different extracts from two different biopsies 
of the same muscle; n = 7 m. gastrocnemius samples).
Intra-assay reliability showed very similar values between measurements (mean difference: 0.6 ± 4.0%). No 
statistically significant differences between measurements were shown (t = 0.144; p = 0.887), indicating that 
HPLC is free of systematic errors. A high ICC (0.996, 95%CI = 0.987–0.999) and low CV (2.7%) were shown 
between measurements (Fig. 4, panel A). Inter-extract reliability also showed very similar values between meas-
urements (mean difference: 1.0 ± 4.5%), with no statistically significant differences between them (t = 0.519; 
p = 0.615). A high ICC (0.988, 95%CI = 0.956–0.997) and low CV (3.2%) were shown between measurements 
(Fig. 4, panel B). Inter-biopsy reliability analysis also showed very similar values between measurements (mean 
difference = 1.1 ± 6.0%) with no statistically significant differences between them (t = −0.588; p = 0.578). A high 
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ICC (ICC = 0.957, 95%CI = 0.750–0.993) and low CV (3.9%) were shown between measurements (Fig. 4, panel 
C).
Validity assessment of 1H-MRS to quantify carnosine in-vivo in human skeletal muscle. To 
thoroughly assess the validity of 1H-MRS to quantify carnosine in human skeletal muscle, a series of in-vivo 
studies were conducted in young healthy men aiming to examine test-retest reliability, discriminant validity (i.e., 
ability to differentiate conditions of knowingly different carnosine concentrations) and convergent validity (i.e., 
agreement with quantification via HPLC in extracts obtained from muscle biopsy samples).
Poor reliability of 1H-MRS to quantify muscle carnosine. 1H-MRS test-retest reliability was assessed in two dif-
ferent conditions: with (n = 10) and without (n = 5) the participant being removed from the scanner and the voxel 
Figure 1. Signal obtained from a phantom containing a 12 mmol·L−1 solidified pure carnosine solution 
(top panel) and signal obtained in vivo from the m. gastrocnemius of a similar carnosine concentration 
(10.4 mmol·L−1) (bottom panel). On the left, the signals are plotted as raw data; water peak is circled and 
the frequency area containing the carnosine peaks is indicated by the vertical dashed lines. On the right, 
the cut window of the frequency area containing the carnosine peaks are shown, indicating the signal after 
normalization.
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being repositioned and re-shimmed before the second test. When the participants were not removed from the 
scanner, good reliability was obtained between measurements, (ICC = 0.924, 95%CI = 0.451–0.992; CV = 6.6%; 
Fig. 5, upper panel). However, reliability indexes were poorer when individuals were removed and subsequently 
repositioned on the equipment, and the voxel was repositioned and re-shimmed (ICC = 0.775, 95%CI = 0.325–
0.939; CV = 16.9%; Fig. 5, lower panel). No statistically significant differences were shown between tests in both 
conditions, indicating that 1H-MRS is free of systematic errors.
1H-MRS has adequate discriminant, but poor convergent validity to quantify muscle carnosine. Muscle carnosine 
was determined using both 1H-MRS and HPLC in the m. gastrocnemius of 14 participants before and after 4 
weeks of β-alanine supplementation. Both methods were able to detect a significant increase in muscle carnosine 
after β-alanine supplementation (Fig. 6, panel A). When comparing the absolute and relative delta increase in 
muscle carnosine measured by both methods, no statistically significant differences were shown for the mean 
values between methods (Fig. 6, panel B), therefore indicating that 1H-MRS has adequate discriminant validity. 
However, when individual data were analysed and delta changes (either absolute or percent changes) obtained 
with 1H-MRS are plotted against HPLC, a large disagreement was shown, and most of the measurements were 
further away far from the line of identity (Fig. 6, panels C and D). This is confirmed by the Bland-Altman plot 
including the entire data set, which shows a large disagreement between methods, especially at low carnosine 
concentrations (Fig. 6, panel E). This is further confirmed by plotting individual absolute values obtained with 
1H-MRS against HPLC, which shows that most data fall far from the identity line (Fig. 6, panel F).
Discussion
Considering the growing attention that carnosine in muscle has been receiving due to its potential ergogenic and 
therapeutic properties, quantifying this dipeptide in muscle tissue is becoming an increasingly necessary proce-
dure. As such, the use of an accurate, reliable and sensitive method for carnosine quantification is of the utmost 
importance. Although non-invasive alternatives for muscle biopsies are unquestionably important, their validity 
as well as their limitations must be known. Since no study to date has thoroughly assessed 1H-MRS validity for 
muscle carnosine quantification, we performed a series of in vitro and in vivo experiments to examine several 
aspects of 1H-MRS validity (i.e., signal linearity, matrix effect, reliability, discriminant and convergent validity). 
To be certain that HPLC is a reliable method for muscle carnosine determination and that it could be used as the 
reference in this study, we also examined its reliability, which showed excellent repeatability in all instances (i.e., 
intra-assay, inter-extract, and inter-biopsy).
Figure 2. Signal linearity obtained from phantoms containing different concentrations of imidazole, histidine 
and carnosine. Concentrations are equimolar in imidazole.
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The present investigation revealed important methodological issues that must be considered when interpret-
ing muscle carnosine values obtained in vivo by 1H-MRS. Due to the small signal amplitude14–17, we sought to 
be certain that the carnosine signal is quantifiable across the entire physiological range, including the expected 
values for the lowest and highest extremes of human population, such as those reported in vegetarians9 and 
bodybuilders22. In this regard, 1H-MRS showed excellent linearity when carnosine is quantified in phantoms 
containing pure carnosine, as well as a clear ability to detect and quantify carnosine even in the lowest range. 
Excellent in vitro linearity has also been shown by Özdemir et al.11. However, it must be noted that this does 
not necessarily imply that quantifying the carnosine signal in vivo would be equally precise and linear as the for 
in vitro signal. Although the in vivo signal has a good signal to noise ratio of (~13 in our study), it is clearly 
broader, of lower amplitude, and presented higher baseline noise when compared to the in vitro signal (signal to 
noise ratio ~18 in our study). Such phenomenon is similar to the matrix effect often seen in analytical methods 
and can be explained by the potential influence of fat and bone tissues to the carnosine signal23,24, as well as the 
large number of compounds with magnetic nuclei present in human muscle. The magnetic interaction among 
neighbouring, non-equivalent, magnetic nuclei causes a phenomenon known as spin-spin coupling, where the 
magnetic field generated by each proton interferes with the other one, resulting in splitting and broadening of 
signal peaks25. This phenomenon can be better observed for the C4-H peak, since its position in the imidazole 
ring and its proximity with the nearest protons makes its signal more susceptible to spin-spin coupling effects14. 
As herein demonstrated, carnosine peaks already present a small amplitude in the 1H-MRS17; when these sig-
nals are divided or further weakened by the spin-spin coupling, a decrease in signal occurs, resulting in poorer 
signal-to-noise ratio21. In individuals with low muscle carnosine content, increased error is to be expected, since 
peak amplitude is naturally lower and, therefore, very close to the basal noise. This is supported by the increased 
Figure 3. Spectra obtained from phantoms containing 12.5 mmol·L−1 of carnosine, histidine and imidazole 
(panels A, B and C, respectively) and bovine serum albumin (BSA) (panel D). Signals were quantifiable in all 
spectra, except BSA.
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disagreement between 1H-MRS and the reference method shown in the Bland-Altman plot when carnosine con-
centrations are near to the lowest range.
To investigate the potential impact of the imidazole ring present in other molecules (e.g., free imidazole, free 
histidine, carnosine analogues and histidine residues in proteins) on the carnosine signal detected by 1H-MRS, 
a series of acquisitions were performed in phantoms containing pure carnosine, imidazole, histidine, and BSA. 
Although the best signal quality was obtained with carnosine, quantifiable signals were also obtained with imi-
dazole and free histidine. This indicates that small imidazole-containing molecules might constitute a potential 
source of error, although they are likely of low relevance for the skeletal muscle since they are expressed in very 
low concentrations in comparison with carnosine26. However, this may be problematic when carnosine is to be 
measured in tissues expressing higher concentrations of small imidazole-containing molecules. Conversely, no 
signal was obtained with BSA, probably due to its large size (~66 kDa). Large molecular size leads to slow tum-
bling and correspondingly short spin-spin relaxation times (T2), resulting in a complex spectrum with broad 
peaks of low amplitude that do not surpass noise level. Accordingly, 1H-MRS data become unreliable for proteins 
larger than 30 kDa at room temperature27. These results indicate that large imidazole-rich proteins such as hae-
moglobin do not represent a source of error, although smaller histidine-rich proteins, such as myoglobin (17 kDa, 
4.7 mg·g−1 wet muscle, 11% histidine) could still contribute to the in vivo signal. However, we unfortunately were 
unable to prepare a phantom with purified myoglobin for further verification. Hence, whether myoglobin consti-
tutes a source of error requires future clarification.
To assess reliability, convergent and discriminant validity of in vivo 1H-MRS, a series of analyses were con-
ducted. No significant differences were shown between test and retest values, indicating that 1H-MRS is free of 
systematic errors and that the large variation observed is due to random error. Importantly, a remarkable increase 
in test-retest variation (6.6% vs. 16.9%) was shown when the retest was performed with the participant being 
Figure 4. Repeatability analysis of the chromatographic determination of carnosine in muscle samples 
considering the intra-assay variability (same extraction from the same samples measured twice – panel A), 
“inter-extract” variability (different extractions from the same samples, measured in duplicate – panel B) and 
“inter-biopsy” variability (different extractions from different samples, measured in duplicate – panel C). The 
left charts depict test-retest agreement for each individual sample (in comparison with the line of identity) along 
with indexes of reliability. The right charts depict the mean ± SD for test and retest conditions.
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removed from and then relocated to the scanner, which is a more “real-world” representation of studies assessing 
muscle carnosine before and after an intervention. Such an increase in variation indicates that voxel positioning 
and shimming are major sources of random error in 1H-MRS. In the present study, all possible measures were 
taken to ensure that voxel would be positioned in the same location (i.e., the same experienced technician was 
responsible for voxel positioning in all exams; voxel positioning at “retest” was done with the image depicting 
voxel position at “test” as a guide). Nonetheless, a large variation was observed between test and retest measure-
ments, indicating that even small differences in voxel position have a large impact on the results. Such a large 
variation arising from voxel repositioning and re-shimming is somewhat expected for a metabolite with a broad 
signal and of low amplitude, such as carnosine, since similar levels of variation have been reported for other 
metabolites of much sharper and high amplitude signals28. In addition, the ~17% variation reported in this study 
is not too dissimilar to previous investigations11,13,17.
One explanation for the larger variation of 1H-MRS is the non-homogeneity of carnosine distribution in the 
skeletal muscle. Carnosine content is greater in type II than type I muscle fibres9; therefore, the inevitable change 
in muscle site when performing two 1H-MRS, albeit small, may cause sampling sites to have different fiber type 
composition, adding a source of measurement error. However, slight changes in sampling sites likely occurred 
with muscle biopsies and, yet, the variation for HPLC was lower. This means that other factors may play a role in 
the increased variability in 1H-MRS, such as the proximity with tissues that may cause signal interference (e.g., 
adipose tissue). The fat signal often appears bright in many important clinical imaging sequences and can obscure 
other signals29,30. Thus, adipose tissue near or at the data acquisition site can contribute to the increased varia-
bility. Additionally, 1H-MRS appears to be more sensitive to changes in sampling sites because shimming and 
spin-spin coupling are dependent on the angle between spins and the magnetic field, which may alter with slight 
changes in sampling sites. Such orientation-dependence is particularly true for the carnosine signal in human 
skeletal muscle31. Participants’ motion during the exam could also disrupt data acquisition, thereby contributing 
to 1H-MRS variability32, although all participants were requested to remain still during the entire duration of the 
exams.
Another putative contributing factor for the poor reliability of 1H-MRS in our study is the spectral correc-
tion that is applied as default in the Phillips post-acquisition data processing algorithm (Dr Wim Derave, per-
sonal communication). Developed to optimise the spectrum obtained in brain, the default mode (on) herein 
Figure 5. Repeatability analysis of the in vivo 1H-MRS determination of carnosine. In the upper panel, test 
and retest were undertaken without removing the participant from the scanner and without repositioning and 
replacing the voxel. In the lower panel, the participants were removed from the scanner after test and the retest 
was undertaken with the voxel being repositioned and re-shimmed. The left charts depict test-retest agreement 
for each individual test (in comparison with the line of identity) along with indices of reliability. The right charts 
depict mean ± SD for test and retest.
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used corrects the metabolite spectra using the water-unsuppressed spectra. However, if fat tissue is present in 
the voxel region, the baseline can be distorted, possibly affecting the carnosine signal. Although this has never 
been reported in the literature, we tested whether changing the spectral mode to “off ” impacts carnosine signal. 
Figure 6. Discriminant validity of 1H-MRS for in vivo muscle carnosine quantification, and convergent 
validity of 1H-MRS vs. HPLC for muscle carnosine determination. Panel A: Individual (represented in 
letters) and mean ± SD values for muscle carnosine measured using both methods before and after β-alanine 
supplementation. Panel B: Absolute (left chart) and relative (right chart) post-pre delta values for muscle 
carnosine measured using both methods in response to β-alanine supplementation. Panel C: Absolute post-pre 
delta values obtained using both methods plotted against the identity line (i.e., representing 100% agreement 
between methods). Panel D: Relative post-pre delta values obtained using both methods plotted against the 
identity line (i.e., representing 100% agreement between methods). Panel E: Bland-Altman plot for percent 
differences between methods. Panel F: pooled pre and post data for muscle carnosine values obtained using 
both methods plotted against the identity line (i.e., representing 100% agreement between methods).
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Interestingly, no significant differences were observed when the spectra obtained with the correction “on” were 
reconstructed to the mode “off ” (n = 11 spectra obtained from 5 young men; p = 0.69 mode “on” vs. mode “off ”). 
Moreover, we observed no improvement in test-retest reliability (removing and repositioning the participants in 
the scanner) by changing the spectral correction mode to “off ” (CV = 36.8%, n = 3). Thus, it is unlikely that the 
results herein presented are artifactual findings specific to our acquisition settings, and they probably reflect true 
limitations of the 1H-MRS to quantify carnosine in skeletal muscle.
The discriminant validity study showed that 1H-MRS, despite having large variation owing to random errors, 
is sensitive to detect group-mean increases in muscle carnosine in response to β-alanine supplementation. The 
changes shown with 1H-MRS are similar to those reported in other studies33. Yet, when comparing the ability 
of 1H-MRS to detect changes in muscle carnosine with HPLC, a high degree of disagreement between methods 
was shown. Likewise, a large degree of disagreement was shown in all instances where 1H-MRS and HPLC were 
compared, which becomes particularly evident when the results are analysed at the individual level (Fig. 6). The 
disagreement seemed to increase when participants showed smaller carnosine content, possibly due to 1H-MRS 
signal characteristics. As discussed, the carnosine peak amplitude in 1H-MRS makes it prone to suffer noise inter-
ference, which is more pronounced at lower concentrations. On the other hand, carnosine peaks in the HPLC 
chromatogram are large, sharp and easily quantifiable across the entire physiological range. Previous studies in 
the literature also appear to support the discrepancy between 1H-MRS and HPLC measurements of muscle car-
nosine, since HPLC studies consistently show 40–80% increases in muscle carnosine in response to 4 weeks of a 
6.4 g.day−1 dosage of β-alanine supplementation8,9,19, whereas studies using 1H-MRS show much larger increases 
of 140–160% in muscle carnosine12, or no increase at all13 following similar β-alanine supplementation protocols. 
In line with this, a recent meta-analysis including numerous studies assessing the effects of β-alanine supple-
mentation on muscle carnosine showed that the method (HPLC vs. 1H-MRS) is a factor that significantly affects 
muscle carnosine outcomes (Rezende et al., submitted34). It seems that the strength of the magnetic field of the 
scanner could be an important factor affecting the validity of muscle carnosine measurements. While the sole 
study unable to detect increases in muscle carnosine following β-alanine supplementation used a 1.5T scanner13, 
improved reliability was shown with carnosine being quantified with a 7 T scanner17.
A potential limitation of this study is that the results were obtained from the m. gastrocnemius medialis, known 
to have a mixed proportion of type I and II fibers. Hence, it remains to be elucidated whether 1H-MRS shows bet-
ter measurement performance for carnosine quantification in a more homogeneous muscle. In addition, consid-
ering that physically active participants were recruited for the present study and that local adipose tissue appeared 
to be an important factor interfering with 1H-MRS signal23, we cannot rule out the possibility that 1H-MRS is 
more reliable in individuals with lower body fat, such as athletes.
To conclude, 1H-MRS is capable of measuring carnosine in muscle tissue and is sensitive to detect overall 
changes in muscle carnosine brought about by β-alanine supplementation. However, 1H-MRS has a high degree 
of variation due to random error associated with a large effect that minor variations in voxel positioning has on 
the carnosine signal. This also results in poor convergent validity. This makes quantification problematic, par-
ticularly in regions surrounded by fat tissue, in individuals with high levels of body fat, and in individuals with 
low muscle carnosine levels. Caution should be exercised when interpreting muscle carnosine quantification data 
obtained with 3-T 1H-MRS, especially when absolute quantification is used. Future studies assessing muscle car-
nosine non-invasively should opt for scanners with stronger magnetic fields, such as 7-T 1H-MRS, for improved 
resolution.
Methods
ethical approval. The study was approved by the Ethics Committee of the School of Medicine of the 
University of Sao Paulo (approval number – 43986415.3.0000.0065) and conformed to the 2013 version of the 
Declaration of Helsinki. All participants signed the written informed consent term before taking part of the study.
In vitro investigation. Thirteen 0.5 L cylindrical bottles mimicking a human calf were filled with solidified 
solutions of carnosine, imidazole, histidine or BSA. Phantoms of 6 different carnosine concentrations (3.0, 4.5, 
6.0, 12.5, 25.0 and 50.0 mmol·L−1) were prepared to assess signal linearity within the physiological range and 
signal behaviour near to the lowest physiological range. Phantoms of 3 different imidazole and histidine concen-
trations (12.5, 25.0 and 50.0 mmol·L−1 each) were prepared to examine whether the signals would differ between 
imidazole-containing substances. One phantom containing BSA (the equivalent to 12.5 mmol·L−1 of imidazole) 
was prepared to assess whether imidazole-residues in large size molecules (e.g., protein) could emit a signal at 
the same chemical shift (7 and 8 ppm). All phantoms were solidified by melting agarose 2% w:v in autoclaved 
ultra-pure water prior to adding carnosine, imidazole, histidine or BSA. Phantom concentrations were calculate 
based on the imidazole content so that all concentrations were equimolar to 12.5 mmol·L−1 of imidazole. The 
12.5 mmol·L−1 concentration for BSA was chosen because this is nearly the maximum achievable within the sol-
ubility of BSA and it represents a mid-range physiological concentration of carnosine in human skeletal muscle.
For the present investigation, a 3 Tesla whole-body magnetic resonance scanner (Achieva Intera, Philips, 
Best, The Netherlands) equipped with an 8-channel knee coil was used. All the spectra were acquired using sin-
gle voxel point-resolved spectroscopy (PRESS) localization with the following parameters: TR/TE = 6000/30 ms, 
voxel size = 10 × 10 × 10 mm3, number of averages (NEX) = 224, 2048 data points with a spectral width of 2000 
Hz. The total acquisition time was 20 min for each phantom. All spectra were processed in jMRUI software. 
Residual water and lipid peaks were removed by a Hankel Lanczos Squares Singular Values Decomposition 
(HSVLD) algorithm from the carnosine, histidine and BSA spectra, and their C2-H and C4-H peaks were fitted 
with Advanced Method for Accurate, Robust and Efficient Spectral fitting (AMARES) using single Lorentzian line 
shapes. Carnosine’s signal linearity was evaluated by linear regression of the “carnosine concentration vs. signal” 
calibration curve.
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In vivo investigation. Sixteen young, healthy, physically active men volunteered to participate, two of whom 
could not complete the entire study due to personal reasons. Therefore, 14 participants (age: 27 ± 5 years; body 
mass: 82.9 ± 11.8 kg; stature: 1.77 ± 0.06 m; body mass index: 26.3 ± 2.4 kg·m2) completed all tests. Participants 
were fully informed of possible risks and discomforts associated with participation. They were requested to main-
tain similar levels of physical activity and dietary patterns for the duration of the study. Exclusion criteria were: 
(i) use of supplements containing creatine or β-alanine in the 3 months and 6 months prior to the study; (ii) use 
of anabolic steroids; (iii) chronic use of glucocorticoids; (iv) chronic-degenerative disease and/or condition that 
affected the locomotor apparatus, and (v) any condition that would prevent them from undertaking the proposed 
tests (e.g., metallic prostheses that could interfere with 1H-MRS quality).
Participants were assessed for muscle carnosine before and after a 4-week period of β-alanine supplementa-
tion. To assess convergent validity, muscle samples were obtained from the same group of participants immedi-
ately after 1H-MRS, both before and after β-alanine supplementation, so that the results obtained with 1H-MRS 
could be compared with those obtained with HPLC. Muscle carnosine concentrations obtained with 1H-MRS 
were converted to the same unit of muscle carnosine content (i.e., from mmol·L−1 to mmol·kg−1 of dry tissue) 
for a clearer comparison between methods. The 1H-MRS in vivo and muscle biopsy assessments were individ-
ually standardized so that each participant performed their PRE and POST-sessions at the same time of day. 
Participants were requested to abstain from alcohol and unaccustomed exercise in the 48 hours prior to the exper-
imental sessions. Participants were instructed to arrive at the laboratory at least 2 hours following their last meal. 
Ad libitum water consumption was allowed before and after the sessions.
β-alanine was provided in 800-mg tablets (CarnoSyn, Natural Alternatives International, Inc., Carlsbad, 
CA) and the participants were asked to take 2 tablets along with meals, four times per day, totalling 6.4 g·d−1 of 
β-alanine. This intervention was intentionally chosen due to its highly consistent effects on muscle carnosine2,8. 
All 16 participants completed a baseline assessment for carnosine quantification in the medial portion of m. 
gastrocnemius of the right leg using both 1H-MRS and HPLC. Carnosine quantification via 1H-MRS was not 
possible in one participant due to a peak of very small amplitude with baseline below zero. Therefore, the analysis 
of convergent validity was conducted on 15 participants. To minimize differences between methods owing to 
variations in sampling sites, biopsy sites were intentionally taken from the closest possible sites to those where 
the spectra were obtained. This was ensured with the physician examining the image of the voxel position before 
defining the location and the depth the biopsy needle would be inserted. Following the supplementation period, 
the 14 participants who completed the entire study were again assessed for muscle carnosine using both 1H-MRS 
and HPLC. The responses to supplementation were used to compare the discriminant validity between methods.
A sub-sample of 10 participants volunteered for the test-retest reliability assessment of 1H-MRS with voxel 
repositioning and re-shimming. They undertook the first 1H-MRS, left the room, waited for 5 minutes and then 
were repositioned back on the machine for the second 1H-MRS. The voxel was repositioned as closely as possible 
to the site where it was positioned in first test; this was achieved using an image of the voxel position obtained in 
the first 1H-MRS as a guide. Another sub-sample of 5 participants volunteered for the test-retest reliability assess-
ment of 1H-MRS without voxel repositioning and re-shimming. They undertook the first 1H-MRS and stood still 
for the second 1H-MRS, which was performed immediately after the first.
To assess intra-assay reliability of HPLC, muscle extracts obtained from 15 biopsy samples were analysed in 
duplicate in two independent runs. To assess “inter-extract” reliability of HPLC, two different muscle extracts 
obtained from 11 biopsy samples (m. vastus lateralis) randomly chosen from this same collection were analysed 
in duplicates on different days. To assess “inter-biopsy” reliability of HPLC, two consecutive muscle samples (m. 
gastrocnemius) were obtained from the same incision in a sub-sample of 7 participants who volunteered for this 
study. The second biopsy location was changed by rotating the needle’s window guillotine in 90 degrees, thereby 
sampling the collateral site of the first biopsy.
1H-MRS in vivo assessment. Spectra were acquired using single voxel point-resolved spectroscopy 
(PRESS) localization with the following parameters: TR/TE = 3000/30 ms, voxel size=10 × 10 × 30 mm3, number 
of averages (NEX) = 256, 2048 data points with a spectral width of 2000 Hz. The total acquisition time of the 
1H-MRS was 13.9 min. The 50 mmol·L−1 carnosine phantom was used as an external reference. To that end, an 
acquisition was made using the same parameters as those used in vivo, except for the TR, which was 12000 ms. 
In each in vivo measurement, the right leg of each participant was positioned and was firmly immobilized in the 
knee coil, such that the gastrocnemius muscle was in the centre of the coil. The left leg was supported outside the 
coil to improve comfort and thus minimize leg movement. Voxel location was standardized on the larger calf 
region in the centre of the medial portion of the gastrocnemius muscle of the right leg. The same well-trained and 
experienced biomedical technician was responsible for placing the voxel in all conditions. After placing the voxel, 
a set of images depicting individual voxel location was saved and used to guide positioning in all further exams 
of that individual.
Quantification. Absolute quantification of the carnosine resonance was determined using the following 
equation21:
=
∗ .
= = ∗SV S F F
S F F
ST S F
S F
CM SV
STPt
mmol L0 66 50 /M MT MT
H OV H OMT H OMT
R RT
H OT H ORT
1 2
2 2 1 2 2
2
2 2 2
CM is the concentration of the metabolite in vivo, SV and ST are the signals of the water-corrected metabolite 
in vivo and in vitro; SM is the integral of the carnosine peak in vivo and SR is the integral of the carnosine peak in 
vitro; FMT1 is the correction factor for T1 relaxation of the metabolite in vivo; FMT2 and FRT2 are the correction fac-
tors for metabolic T2 relaxation in vivo and in vitro; SH2OV is the integral of the water peak in vivo and SH2OT is the 
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integral of the water peak in vitro; FH2OMT1 is the correction factor for T1 relaxation of water in vivo; And FH2OMT2 
and FH2ORT2 are the correction factors for T2 relaxation of water in vivo and in vitro. Pt is the temperature correc-
tion factor applied as the signal decreases by 6% between the room temperature (i.e., phantom temperature) and 
body temperature35. For the in vitro signal, it is not necessary to correct the T1 relaxation, since the acquisition 
was performed with a sufficiently long TR (TR = 12000 ms) to neglect this factor. Signals were also corrected by 
water content; since the water content in phantoms is ~100%, a correction factor = 1 was used. For the in vivo 
analyses, a correction factor = 0.66 was used, assuming that ~2/3 of the muscle is water36.
The relaxation correction factors were calculated using the following equations:
=
− −( )
F 1
1 exp
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1
=
− ( )
F 1
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T TE
T
2
2
T1 and T2 values for water and carnosine were taken from the literature, and were assumed to be 1420 ms 
and 32 ms for water in muscle37 and 520 ms and 66 ms for in vivo carnosine11. The T2 values of in vitro water and 
carnosine in vitro (52 ms and 200 ms) were measured using different TEs (31, 61, 99, 150, 228, and 400 ms) with 
TR of 6000 ms and calculated using MATLAB software (The MathWorks, Natick, MA, USA) by fitting data points 
determined using the peak areas of metabolites to a mono-exponential function Ms = M0 exp(−TE/T2). To 
further convert concentration values in mmol·L−1 into the content equivalent in mmol·kg−1 of dry muscle, results 
were multiplied by 3.3, a factor which assumes that for every 1 kg of dry muscle there is 3.3 kg of water. Spectrum 
figures are presented with the raw (untreated) spectrum on the left side and a cut window (framework of the 
target the frequency) on the right. The cut window signal was normalized by the baseline offset to facilitate visual 
comparison between both situations37.
Muscle biopsies. Muscle samples (~70–100 mg) were obtained under local anaesthesia (3 mL, 1% lidocaine) 
from the mid-portion of the m. gastrocnemius using the percutaneous needle biopsy technique with suction38. 
Samples were obtained from the same leg for all experiments. PRE and POST supplementation biopsies were 
taken from incisions made as close as possible to one another. Samples taken for the inter-biopsy reliability anal-
yses were obtained from the same incision, but from slightly different sites, as described above. All samples were 
snap frozen in liquid nitrogen and were subsequently stored at −80 °C until analyses. Samples were freeze-dried 
and dissected free of any visible blood, fat and connective tissue before being powdered and further submitted to 
HPLC determination of carnosine.
Chromatographic determination of histidine-containing dipeptides in whole muscle. 
Deproteinized muscle extracts were obtained from 3–5 mg freeze-dried samples according to the protocol 
described by Harris et al.8. Briefly, samples were deproteinized with 0.5 M HClO4 and neutralized with 2.1 M 
KHCO3. The extracts were then filtered through a 0.22 µm centrifugal PVDF filter unit and stored at −80o C until 
analysis. Total muscle carnosine content was quantified by HPLC (Hitachi, Hitachi Ltd., Tokyo, Japan), according 
to the method described by Mora et al.39. Mobile phases consisted of solvent A, containing 0.65 mM ammonium 
acetate, pH 5.5, in water/acetonitrile (25:75); and solvent B, containing 4.55 mM ammonium acetate, pH 5.5, in 
water/acetonitrile (70:30). The chromatographic separation was developed using an Atlantis HILIC silica col-
umn (4.6 × 150 mm, 3 μm; Waters, Milford, MA, USA) attached to an Atlantis Silica column guard (4.6 × 20 mm, 
3 μm), at room temperature. The analysis conditions comprised of a linear gradient from 0 to 100% of solvent B 
in 13 min at a flow rate of 1.4 mL·min−1. Separation was monitored using a U.V. coupled detector at a wavelength 
of 214 nm.
Statistical analyses. Signal linearity of the in vitro analysis was verified by interpolating signal intensity 
by concentration and calculating Pearson correlation coefficient (r). Test-retest reliability was assessed using: 
(1) a paired sample t-test to check for systematic errors, (2) intraclass correlation coefficient (ICC - two-way 
random, absolute agreement, single-measures) with their respective 95% confidence intervals (95%CI) and 
(3) within-subject mean square root coefficient of variation (CV)40. Test-retest data were plotted to individu-
ally display the distance between data pairs and the identity line. Convergent validity was assessed using: (1) 
an unpaired sample t-test to check for differences between HPLC and 1H-MRS values, for both PRE and POST 
supplementation data sets, and (2) the Bland-Altman plot for percentage differences against mean values for the 
overall data set. HPLC vs. 1H-MRS data was plotted to individually display the distance between data pair and the 
identity line. Discriminant validity was assessed using a paired sample t-test to compare mean carnosine values 
between PRE and POST supplementation period. Effect sizes (ES) for the muscle carnosine content increase after 
β-alanine supplementation were calculated using Cohen’s d. All analyses were conducted in the IBM SPSS soft-
ware (version 20). Bland-Altman was built using the GraphPad Prism software (version 5.03).
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